<DOC>
	<DOCNO>NCT01541579</DOCNO>
	<brief_summary>The current multicentre phase III study propose confirm add-on therapy design compare placebo-control group , efficacy adipose-derived stem cell ( eASCs ) healthy donor treatment complex anal fistula patient Crohn 's disease 24-week period extend follow-up period 104 week .</brief_summary>
	<brief_title>Adipose Derived Mesenchymal Stem Cells Induction Remission Perianal Fistulizing Crohn 's Disease</brief_title>
	<detailed_description>The current multicentre phase III study propose confirm add-on therapy design compare placebo-control group , efficacy adipose-derived stem cell ( eASCs ) healthy donor treatment complex anal fistula patient Crohn 's disease 24-week period extend follow-up period 104 week . Subject perianal fistulising Crohn 's disease treat Cx601 , suspension eASCs , dose 120 million cell administer intralesional injection . The treatment complex perianal fistula local application eASCs intend improve significantly local condition inconvenience ( ambulatory procedure ) minimal risk possible complication ( anal incontinence ) . Therefore , new therapeutic resource expect safe efficacious well expect improve quality life patient highly debilitate chronic condition . This treatment would prevent one main cause anal incontinence , would diminish recurrence fistula disease would reduce drastically significant disorder provoke standard fistula surgery patient . Indeed , patient discharge accord `` One Day Surgical '' procedure ( major ambulatory surgery ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>The reference population consist patient perianal fistulising Crohn´s disease refractory least one follow treatment : antibiotic , immunosuppressant antitumor necrosis factor ( TNF ) . Naïve patient exclude , patient refractory antibiotic represent less 25 % total recruited patient . All must comply follow inclusion criterion : 1 . Signed informed consent . 2 . Patients Crohn 's Disease ( CD ) diagnose least 6 month early accordance accept clinical , endoscopic , histological and/or radiologic criterion . 3 . Presence complex perianal fistula maximum 2 fistula ( internal opening ) maximum 3 external opening , assess clinical assessment MRI . Fistula must drain least 6 week prior inclusion . A complex perianal fistula define fistula meet one follow criterion evolution : High intersphincteric , transsphincteric , extrasphincteric suprasphincteric . Presence ≥ 2 external opening ( tract ) . Associated collection 4 . Nonactive mildly active luminal CD define CDAI ≤ 220 . 5 . Patients either sex age 18 year old 6 . Good general state health accord clinical history physical examination . 7 . For woman childbearing age , must negative serum urine pregnancy test ( sensitive 25 IU human chorionic gonadotropin ( hCG ) ) . Both men woman use appropriate birth control method define investigator . 1 . Presence dominant luminal active Crohn 's disease require immediate therapy . 2 . CDAI &gt; 220 . 3 . Concomitant rectovaginal fistula 4 . Patient naïve specific treatment perianal fistulising Crohn 's disease include antibiotic 5 . Presence abscess collection &gt; 2 cm , unless resolve preparation procedure ( week 3 day 0 ) . 6 . Presence &gt; 2 fistular lesion . 7 . Presence &gt; 3 external opening . 8 . Rectal and/or anal stenosis / active proctitis , mean limitation surgical procedure . 9 . Patient underwent surgery fistula drainage seton placement . 10 . Patient divert stomas 11 . Patient ongoing steroid treatment treat steroid last 4 week 12 . Renal impairment define creatinine clearance 60 ml/min calculate use CockcroftGault formula serum creatinine ≥ 1.5 x upper limit normality ( ULN ) 13 . Hepatic impairment define follow laboratory range : Total bilirubin ≥ 1.5 x ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 2.5 x ULN 14 . Known history abuse alcohol addictive substance 6 month prior inclusion . 15 . Malignant tumour patient prior history malignant tumour , include type fistula carcinoma . 16 . Current recent history abnormal , severe , progressive , uncontrolled hepatic , haematological , gastrointestinal ( except CD ) , endocrine , pulmonary , cardiac , neurological , psychiatric , cerebral disease . 17 . Congenital acquire immunodeficiency . 18 . Known allergy hypersensitivity antibiotic include limited penicillin , streptomycin , gentamicin , aminoglycosides ; Human Serum Albumin ( HSA ) ; Dulbecco Modified Eagle 's Medium ( DMEM ) ; material bovine origin ; local anaesthetic gadolinium ( MRI contrast ) . 19 . Contraindication MRI scan , ( e.g. , due presence pacemaker , hip replacement severe claustrophobia ) . 20 . Major surgery severe trauma within previous 6 month . 21 . Pregnant breastfeed woman . 22 . Patients wish comply study procedure . 23 . Patients currently receive , receive within 3 month prior enrolment clinical study , investigational drug . 24 . Patients previously treat eASCs enrol clinical study . 25 . Subjects need surgery perianal region reason fistulas time inclusion study , surgery foreseen region 24 week treatment administration . 26 . Contraindication anaesthetic procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Perianal fistulising Crohn 's disease .</keyword>
</DOC>